Summary Vitae Pharmaceuticals Inc (Vitae Pharmaceuticals) is a biopharmaceutical company that offers pharmaceutical products. The company discovers and develops and small molecule drugs for diseases with significant unmet medical needs. Its products pipeline includes VTP-34072, BI 1147560, VTP-43742, VTP-38543 and VTP-38443. Vitae Pharmaceuticals’ products address therapeutic areas such as diabetes, Alzheimer’s disease, atopic dermatitis, autoimmune disorders, and acute coronary syndrome. The company utilizes its contour structure-based drug design platform to discover and develop product candidates for validated therapeutic targets. It operates through biotechnology companies for the treatment of metabolic diseases. The company provides services to healthcare sector. Vitae Pharmaceuticals is headquartered in Fort Washington, Pennsylvania, the US.
Vitae Pharmaceuticals Inc (VTAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining...
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 22.214.171.124) pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase...
Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H2 2018 Summary According to the recently published report...
Acne And Related Disorders Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Acne And Related Disorders Global Clinical Trials Review, H2, 2018" provides an overview of Acne And Related Disorders clinical trials scenario.This report provides top line data relating...